SALT LAKE CITY, Utah, Sept. 26, 2023 /PRNewswire/ — DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine,…